- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Drug
- Lead sponsor
- Retina Consultants of Orange County
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Fullerton, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 13,471
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoporosis, Growth Hormone Deficiency
- Interventions
- growth hormone
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 4 more
- Conditions
- Diabetes, Nutrition
- Interventions
- CGM Device
- Device
- Lead sponsor
- Sutter Health
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Therapeutic Conventional Surgery
- Drug · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 4
- States / cities
- Corona, California • Duarte, California • Upland, California + 1 more
- Conditions
- Type 1 Diabetes
- Interventions
- Semaglutide (Rybelsus®), Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 639 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Type 1 Diabetes
- Interventions
- ONBOARD
- Behavioral
- Lead sponsor
- Molly Tanenbaum
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Propranolol
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Single Dose PB1023
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Cushing's Syndrome
- Interventions
- Not listed
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Rochester, Minnesota • Cleveland, Ohio + 1 more
- Conditions
- Foot Ulcer, Foot Ulcer, Diabetic
- Interventions
- Ulcer Measurement Software
- Device
- Lead sponsor
- Linnea Polgreen
- Other
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Diabetes Mellitus, Kidney Transplant; Complications
- Interventions
- Free style libre-2
- Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Lipodystrophy, Familial Partial
- Interventions
- High fat mixed meal
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
- Interventions
- AGEN1423, Botensilimab, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Bruno Bockorny
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
- Interventions
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Drug
- Lead sponsor
- VM Oncology, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 12
- States / cities
- Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 9 more
- Conditions
- Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Interventions
- irofulven
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Testicular Germ Cell Tumor
- Interventions
- immunohistochemistry staining method, laboratory biomarker analysis, radionuclide imaging
- Other · Procedure
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 15 Years to 120 Years · Male only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Cedar Rapids, Iowa + 7 more
- Conditions
- Obesity
- Interventions
- VeSTAL
- Device
- Lead sponsor
- Neurovalens Ltd.
- Industry
- Eligibility
- 22 Years to 80 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- La Jolla, California • Austin, Texas
- Conditions
- Pancreatic Cancer
- Interventions
- Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy, Pancreaticoduodenectomy
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- Benaroya Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- SB Intervention
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type 1 Diabetes
- Interventions
- Not listed
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- ECC5004
- Drug
- Lead sponsor
- Eccogene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Type 1 Diabetes, De Novo Lipogenesis
- Interventions
- Oral Glucose Tolerance Test
- Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 13 Years to 22 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 2 Diabetes, Muscular Atrophy, Sedentary Behavior, Exercise, Pre-diabetes
- Interventions
- Bed Rest Intervention, Exercise Program
- Behavioral
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Orlando, Florida